Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

Authors: Constance J. Martin, Abhishek Datta, Christopher Littlefield, Ashish Kalra, Christopher Chapron, Stefan Wawersik, Kevin B. Dagbay, Christopher T. Brueckner, Anastasia Nikiforov, Francis T. Danehy, Frederick C. Streich, Christopher Boston, Allison Simpson, Justin W. Jackson, Susan Lin, Nicole Danek, Ryan R. Faucette, Pichai Raman, Allan D. Capili, Alan Buckler, Gregory J. Carven, Thomas Schürpf

Published: 2020-03-25

DOI: 10.1126/scitranslmed.aay8456

Source: Full article

---

Abstract

Inhibiting a specific isoform of TGFβ augments the effectiveness of checkpoint blockade therapy in cancer treatment.